|
1.
|
|
10 p, 922.8 KB |
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy : Implications for Complement-Targeted Therapies
/
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Hartung, Hans-Peter (Palacky University Olomouc) ;
Lewis, Richard A. (Cedars Sinai Medical Center) ;
van Doorn, Pieter A. (University Medical Center) ;
Hammond, Timothy R. (Sanofi) ;
Atassi, Nazem (Sanofi) ;
Alonso-Alonso, Miguel (Sanofi) ;
Dalakas, Marinos C. (Neuroimmunology National and Kapodistrian University of Athens Medical School) ;
Universitat Autònoma de Barcelona
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common, heterogeneous, immune-mediated neuropathy, characterized by predominant demyelination of motor and sensory nerves. CIDP follows a relapsing-remitting or a progressive course and causes substantial disability. [...]
2022 -  10.1007/s13311-022-01221-y
Neurotherapeutics, Vol. 19 Núm. 3 (april 2022) , p. 864-873
|
|
|
2.
|
|
10 p, 683.9 KB |
Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program
/
Selmaj, Krzysztof W. (University of Warmia and Mazury) ;
Cohen, Jeffrey A. (Neurological Institute) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Steinman, Lawrence (Stanford University Medical Center) ;
Hartung, Hans-Peter (Medical University Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Cree, Bruce A. C (UCSF University of California San Francisco) ;
Minton, Neil (Bristol Myers Squibb) ;
Sheffield, James K. (Bristol Myers Squibb) ;
Ding, Ning (Bristol Myers Squibb) ;
Kappos, Ludwig (University of Basel) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844
|
|
|
3.
|
|
19 p, 537.2 KB |
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial
/
Cree, Bruce A. C (University of California) ;
Selmaj, Krzysztof W. (University of Warmia and Mazury in Olsztyn) ;
Steinman, Lawrence (Stanford University) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Hartung, Hans-Peter (Medical University of Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Sheffield, James K. (Bristol-Myers Squibb Company) ;
Minton, Neil (Bristol-Myers Squibb Company) ;
Cheng, Chun Yen (Bristol-Myers Squibb Company) ;
Silva, Diego (Bristol-Myers Squibb Company) ;
Kappos, Ludwig (University of Basel) ;
Cohen, Jeffrey A. (Cleveland Clinic) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. Objective: To characterize long-term safety and efficacy of ozanimod. [...]
2022 - 10.1177/13524585221102584
Multiple sclerosis, Vol. 28 Núm. 12 (2022) , p. 1944-1962
|
|
|
4.
|
|
9 p, 2.2 MB |
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS
/
DeLuca, John (Rutgers - The State University of New Jersey, Newark) ;
Schippling, Sven (University of Zurich) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kappos, Ludwig (University of Basel) ;
Cree, Bruce A. C (University of California, San Francisco) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Arnold, Douglas Lorne (McGill University, Montreal) ;
Hartung, Hans Peter (Heinrich Heine University Düsseldorf) ;
Sheffield, James K. (Bristol-Myers Squibb Company) ;
Liu, Hongjuan (Bristol-Myers Squibb Company) ;
Silva, Diego (Bristol-Myers Squibb Company) ;
Cohen, Jeffrey A. (Neurological Institute, Cleveland Clinic) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Cognitive dysfunction, including slowed cognitive processing speed (CPS), is one of the most disabling symptoms of multiple sclerosis (MS). The Symbol Digit Modalities Test (SDMT) is a preferred measure of CPS for MS trials and routine screening. [...]
2021 - 10.1016/j.msard.2020.102673
Multiple Sclerosis and Related Disorders, Vol. 48 (2021) , p. 102673
|
|
|
5.
|
|
27 p, 1.5 MB |
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease : A prospective multicohort study of the ABIRISK consortium
/
Hässler, Signe (Hôpital Pitié-Salpêtrière) ;
Bachelet, Delphine (Hôpital Bichat) ;
Duhaze, Julianne (CHU Ste-Justine Research Center) ;
Szely, Natacha (Paris-Sud University) ;
Gleizes, Aude (Le Kremlin-Bicêtre Hospital) ;
Hacein-Bey Abina, Salima (Paris-Descartes-Sorbonne-Cite University) ;
Aktas, Orhan (University of Düsseldorf) ;
Auer, Michael (Innsbruck Medical University) ;
Avouac, Jerôme (Cochin Hospital) ;
Birchler, Mary (GlaxoSmithKline (Estats Units d'Amèrica)) ;
Bouhnik, Yoram (GETAID (França)) ;
Brocq, Olivier (Princess Grace Hospital) ;
Buck-Martin, Dorothea (Technische Universität München) ;
Cadiot, Guillaume (University Hospital of Reims) ;
Carbonnel, Franck (Hôpital Kremlin-Bicêtre) ;
Chowers, Yehuda (Rambam Health Care Campus) ;
Comabella, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Derfuss, Tobias (University Hospital Basel (Basilea, Suïssa)) ;
Sikkema, Dan (University of Amsterdam) ;
Donnellan, Naoimh (Ipsen Biopharm (Regne Unit)) ;
Doukani, Abiba (Sorbonne Université) ;
Guger, Michael (Kepler University Hospital) ;
Hartung, Hans-Peter (University of Düsseldorf) ;
Kubala Havrdova, Eva (Charles University and General University Hospital, Prague, Czech Republic) ;
Hemmer, Bernhard (Munich Cluster for Systems Neurology) ;
Huizinga, Tom (Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands) ;
Ingenhoven, Kathleen (University of Düsseldorf, Medical Faculty, Department of Neurology, Düsseldorf, Germany) ;
Hyldgaard-Jensen, Poul Erik (Copenhagen University Hospital Rigshospitalet) ;
Jury, Elizabeth C. (University College London) ;
Khalil, Michael (Medical University of Graz) ;
Kieseier, Bernd (University of Düsseldorf) ;
Lindberg, Raija (University Hospital Basel (Basilea, Suïssa)) ;
Loercher, Amy (GlaxoSmithKline (Estats Units d'Amèrica)) ;
Maggi, Enrico (Bambino Gesù Children's Hospital) ;
Manson, Jessica (University College London Hospital) ;
Mauri, Claudia (University College London) ;
Mohand Oumoussa, Badreddine (Sorbonne Université) ;
Montalban, Xavier (St. Michael's Hospital) ;
Nachury, Maria (University Hospital of Lille (França)) ;
Nytrova, Petra (Charles University. Faculty of Medicine in Hradec Králové) ;
Richez, Christophe (Bordeaux University) ;
Ryner, Malin (Karolinska Institutet (Estocolm, Suècia)) ;
Sellebjerg, Finn (Copenhagen University Hospital Rigshospitalet) ;
Sievers, Claudia (University Hospital Basel (Basilea, Suïssa)) ;
Sikkema, Dan (Quanterix Corporation (Estats Units d'Amèrica)) ;
Soubrier, Martin (University Hospital of Clermont Ferrand) ;
Tourdot, Sophie (Paris-Sud University) ;
Trang, Caroline (CHU de Nantes) ;
Vultaggio, Alessandra (Università di Firenze) ;
Warnke, Clemens (University Hospital Köln) ;
Spindeldreher, Sebastian (Integrated Biologix GmbH (Suïssa)) ;
Dönnes, Pierre (SciCross AB (Suècia)) ;
Hickling, Timothy P. (Pfizer (Estats Units d'Amèrica)) ;
Hincelin Mery, Agnès (Sanofi, Chilly-Mazarin, France) ;
Allez, Matthieu (Hôpital Saint-Louis, AP-HP) ;
Deisenhammer, Florian (Innsbruck Medical University) ;
Fogdell-Hahn, Anna (Karolinska Institutet (Estocolm, Suècia)) ;
Mariette, Xavier (Université Paris-Saclay) ;
Pallardy, Marc (Paris-Sud University) ;
Broët, Philippe (Paris-Sud University Hospitals) ;
Universitat Autònoma de Barcelona
Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug antibodies (ADAs) is still limited. [...]
2020 - 10.1371/journal.pmed.1003348
PLoS Medicine, Vol. 17 (october 2020)
|
|
|
6.
|
|
8 p, 976.6 KB |
Efficacy and safety of ozanimod in multiple sclerosis : Dose-blinded extension of a randomized phase II study
/
Cohen, Jeffrey A. (Mellen Center for MS Treatment and Research, Cleveland Clin) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Arnold, Douglas Lorne (McGill University, Montreal) ;
Bar-Or, Amit (University of Pennsylvania. Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology) ;
Selmaj, Krzysztof W. (Center for Neurology, Łódź, Poland) ;
Steinman, Lawrence (Stanford University Medical Center) ;
Havrdová, Eva K. (Charles University. Department of Neurology and Center for Clinical Neuroscience) ;
Cree, Bruce A. C. (University of California. UCSF Weill Institute for Neurosciences) ;
Montalbán, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Hartung, Hans-Peter (Heinrich Heine University. Department of Neurology) ;
Huang, Vivian (Celgene Corporation, San Diego, CA) ;
Frohna, Paul (Celgene Corporation, San Diego, CA) ;
Skolnick, Brett E. (Celgene Corporation, San Diego, CA) ;
Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa))
Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0. [...]
2018 - 10.1177/1352458518789884
Multiple sclerosis, Vol. 25 (july 2018) , p. 1255-1262
|
|
|
7.
|
|
11 p, 1.3 MB |
Multicentre comparison of a diagnostic assay : aquaporin-4 antibodies in neuromyelitis optica
/
Waters, Patrick (University of Oxford) ;
Reindl, Markus (Medical University of Innsbruck) ;
Saiz, Albert (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Schanda, Kathrin (Medical University of Innsbruck) ;
Tuller, Friederike (Medical University of Innsbruck) ;
Kral, Vlastimil (Zdravotni ustav se sidlem v Usti nad Labem, Centrum imunologie a mikrobiologie) ;
Nytrova, Petra (Charles University. Faculty of Medicine in Hradec Králové) ;
Sobek, Ondrej (Topelex Ltd) ;
Nielsen, Helle Hvilsted (Odense University Hospital (Dinamarca)) ;
Barington, Torben (Odense University Hospital (Dinamarca)) ;
Lillevang, Søren T. (Odense University Hospital (Dinamarca)) ;
Illes, Zsolt (University of Pécs) ;
Rentzsch, Kristin (Euroimmun AG) ;
Berthele, Achim (Klinikum rechts der Isar der TU München, Klinik für Neurologie) ;
Berki, Tímea (University of Pécs) ;
Granieri, Letizia (Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital San Luigi Gonzaga, Regional Referring Multiple Sclerosis Centre) ;
Bertolotto, Antonio (Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital San Luigi Gonzaga, Regional Referring Multiple Sclerosis Centre) ;
Giometto, Bruno (Azienda ULSS 9 Treviso) ;
Zuliani, Luigi (Azienda ULSS 9 Treviso) ;
Hamann, Dörte (Sanquin Diagnostic Services, Department of Immunopathology and Blood Coagulation, Amsterdam) ;
van Pelt, E. Daniëlle (MS Centre ErasMS, Erasmus MC) ;
Hintzen, Rogier (MS Centre ErasMS, Erasmus MC) ;
Höftberger, Romana (Medical University of Vienna. Institute of Neurology) ;
Costa, Carme (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Comabella, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tintoré, Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Siva, Aksel (Istanbul University, Cerrahpasa Medical School) ;
Altintas, Ayse (Istanbul University, Cerrahpasa Medical School) ;
Deniz, Günnur (Istanbul University, Institute of Experimental Medicine) ;
Woodhall, Mark (University of Oxford) ;
Palace, Jacqueline (University of Oxford) ;
Paul, Friedemann (Charité - Universitätsmedizin Berlin) ;
Hartung, Hans-Peter (Heinrich-Heine-University Düsseldorf) ;
Aktas, Orhan (Heinrich-Heine-University Düsseldorf) ;
Jarius, Sven (University of Heidelberg) ;
Wildemann, Brigitte (University of Heidelberg) ;
Vedeler, Christian (Haukeland University Hospital (Bergen, Noruega)) ;
Ruiz, Anne (Lyon Neurosciences Research Centre, Neuro-inflammation and Neuro-oncology Team) ;
Leite, M. Isabel (University of Oxford) ;
Trillenberg, Peter (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Probst, Monika (Institute for Quality Assurance) ;
Saschenbrecker, Sandra (Euroimmun AG) ;
Vincent, Angela (University of Oxford) ;
Marignier, Romain (Lyon Neurosciences Research Centre, Neuro-inflammation and Neuro-oncology Team) ;
Universitat Autònoma de Barcelona
Antibodies to cell surface central nervous system proteins help to diagnose conditions which often respond to immunotherapies. The assessment of antibody assays needs to reflect their clinical utility. [...]
2016 - 10.1136/jnnp-2015-312601
Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 87 (april 2016) , p. 1005-1015
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
